Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-guided IP chemotherapy in gastric cancer
NCT07034742Phase 1Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2025
- Primary completion
- Jan 2026
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluorouracil, paclitaxel, cisplatin and aldesleukin in gastric adenocarcinoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: 2-year peritoneal metastasis-free survival rate. Started Jun 2025; status: recruiting.
02
Drugs
fluorouracilpaclitaxelcisplatinaldesleukin
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT07034742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07034742.